|
Neoplasms
|
0.050 |
GeneticVariation
|
group |
BEFREE |
We previously reported that TLR8 expression was increased directly by the tumor suppressor and transcription factor p53 via a single nucleotide polymorphism (SNP) (rs3761624) in the TLR8 promoter, thereby placing TLR8 in the p53/immune axis.
|
31430261 |
2019 |
|
Coronary Artery Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We investigated whether TLR8 Met1Val and TLR8-129G>C single nucleotide polymorphisms (SNPs rs3764879 and rs3764880) are associated with CAD in the Chinese population.
|
18985439 |
2009 |
|
Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
We hypothesized that specific TLR members (TLR2, TLR3, TLR4, TLR8) may play a role in atherosclerosis progression and its accompanying inflammatory response.
|
28478461 |
2017 |
|
Atherosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
We hypothesized that specific TLR members (TLR2, TLR3, TLR4, TLR8) may play a role in atherosclerosis progression and its accompanying inflammatory response.
|
28478461 |
2017 |
|
Pneumonia
|
0.010 |
Biomarker
|
disease |
BEFREE |
We here used a recently developed chemical antagonist of TLR8 to determine its role in human primary monocytes challenged with <i>S. aureus</i>, GBS, <i>Streptococcus pneumonia, Pseudomonas aeruginosa</i>, and <i>E. coli</i>.
|
31214180 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have found that seven of these genes exhibit a significant (FDR<0.05) association with SLE, both confirming some genes that have earlier been found to be associated with SLE (PTPN22 and IRF5) and presenting novel findings of genes (KLRG1, interleukin-16, protein tyrosine phosphatase receptor type T, toll-like receptor (TLR)8 and CASP10), which have not been reported earlier.
|
19440200 |
2009 |
|
Meniere Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
We genotyped SNV of TLR3, TRL7, TLR8 and TLR10 in 863 Spanish and 150 Italian patients with Meniere's disease (MD) and 1,013 controls by using Taqman assays.
|
23370977 |
2013 |
|
Autoimmune Diseases
|
0.070 |
Biomarker
|
group |
BEFREE |
We found that the consequence of self-recognition via TLR8 results in a constellation of diseases, strikingly distinct from those related to TLR7 signaling, and points to specific inflammatory diseases that may benefit from inhibition of TLR8 in humans.
|
24277153 |
2013 |
|
Tuberculosis
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
We found that four polymorphisms in the TLR8 gene on chromosome X showed evidence of association with TB susceptibility in males, including a non-synonymous polymorphism rs3764880 (Met1Val; P = 0.007, odds ratio (OR) = 1.8, 95% c.i.= 1.2-2.7).
|
18927625 |
2008 |
|
Rheumatoid Arthritis
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
We focussed on three single allelic variants, N248S in TLR1, Q11L in TLR7 and M1V in TLR8 based on the allelic frequencies in both patient and control populations, the predicted impact on protein function and the novelty in RA research.
|
28495399 |
2017 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
We explored the status of expression and function of TLR7, TLR8, and TLR9 in primary human Langerhans cells (LCs) isolated from cervical tumors.
|
23221735 |
2013 |
|
Complete atrioventricular block
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We evaluated TLR8 expression and antiviral function in vitro by real-time RT-PCR and flow cytometry analysis using fresh PBMCs obtained from CHB patients compared to healthy controls.
|
28236535 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrate that the secretion of CXCL4 is under the control of phosphatidylinositol 3-kinase δ and is due to the aberrant presence of TLR8 on pDCs of SSc patients, which is not seen in healthy donors or in lupus pDCs, and that CXCL4 primarily acts by potentiating TLR8- but also TLR9-induced IFN production by pDCs.
|
29321259 |
2018 |
|
Lupus Erythematosus
|
0.030 |
Biomarker
|
disease |
BEFREE |
We demonstrate that the secretion of CXCL4 is under the control of phosphatidylinositol 3-kinase δ and is due to the aberrant presence of TLR8 on pDCs of SSc patients, which is not seen in healthy donors or in lupus pDCs, and that CXCL4 primarily acts by potentiating TLR8- but also TLR9-induced IFN production by pDCs.
|
29321259 |
2018 |
|
Lupus Vulgaris
|
0.020 |
Biomarker
|
disease |
BEFREE |
We demonstrate that the secretion of CXCL4 is under the control of phosphatidylinositol 3-kinase δ and is due to the aberrant presence of TLR8 on pDCs of SSc patients, which is not seen in healthy donors or in lupus pDCs, and that CXCL4 primarily acts by potentiating TLR8- but also TLR9-induced IFN production by pDCs.
|
29321259 |
2018 |
|
Lupus Erythematosus, Discoid
|
0.020 |
Biomarker
|
disease |
BEFREE |
We demonstrate that the secretion of CXCL4 is under the control of phosphatidylinositol 3-kinase δ and is due to the aberrant presence of TLR8 on pDCs of SSc patients, which is not seen in healthy donors or in lupus pDCs, and that CXCL4 primarily acts by potentiating TLR8- but also TLR9-induced IFN production by pDCs.
|
29321259 |
2018 |
|
Systemic Scleroderma
|
0.020 |
Biomarker
|
disease |
BEFREE |
We demonstrate that the secretion of CXCL4 is under the control of phosphatidylinositol 3-kinase δ and is due to the aberrant presence of TLR8 on pDCs of SSc patients, which is not seen in healthy donors or in lupus pDCs, and that CXCL4 primarily acts by potentiating TLR8- but also TLR9-induced IFN production by pDCs.
|
29321259 |
2018 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
We conclude that p53 can strongly influence TLR8-mediated immune responses and that knowledge of the p53-responsive SNP can inform diagnosis and prognosis of RSV disease and other diseases that might have a TLR8 component, including cancer.
|
31430261 |
2019 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
We conclude that p53 can strongly influence TLR8-mediated immune responses and that knowledge of the p53-responsive SNP can inform diagnosis and prognosis of RSV disease and other diseases that might have a TLR8 component, including cancer.
|
31430261 |
2019 |
|
Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site
|
0.010 |
Biomarker
|
disease |
BEFREE |
We conclude that p53 can strongly influence TLR8-mediated immune responses and that knowledge of the p53-responsive SNP can inform diagnosis and prognosis of RSV disease and other diseases that might have a TLR8 component, including cancer.
|
31430261 |
2019 |
|
HIV-1 infection
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We conclude that HIV-1 infection induced the expression of pro-IL-1β via TLR8-mediated mechanisms and activated caspase-1 through the NLRP3 inflammasome to cleave pro-IL-1β into bioactive IL-1β.
|
24939850 |
2014 |
|
Squamous cell carcinoma of the head and neck
|
0.020 |
Biomarker
|
disease |
BEFREE |
VTX-2337 (USAN: motolimod) is a selective toll-like receptor 8 (TLR8) agonist, which is in clinical development as an immunotherapy for multiple oncology indications, including squamous cell carcinoma of the head and neck (SCCHN).
|
26928328 |
2016 |
|
Idiopathic Inflammatory Myopathies
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Toll-like receptor 7 (TLR-7), TLR-8, and interferon (IFN)-induced genes are expressed in patients with idiopathic inflammatory myositis.
|
29569859 |
2018 |
|
Tuberculosis, Pulmonary
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Toll-like receptor (TLR) sensors such as TLR2, TLR4, TLR8, and TLR9 are known to play a pivotal role in PTB via modulating sensor expression and/or effector responses.
|
25248338 |
2014 |
|
Tumor Progression
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Toll-like receptor (TLR) 7 and TLR8 expression on CD133+ cells in colorectal cancer points to a specific role for inflammation-induced TLRs in tumourigenesis and tumour progression.
|
20728343 |
2010 |